All Stories

Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease

Abeona is gearing up for a third-quarter launch of its new topical gene therapy after an FDA approval.

Apr 29, 2025 - 14:47
 0
Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease
Abeona is gearing up for a third-quarter launch of its new topical gene therapy after an FDA approval.
Read More

Tags:

Previous Article

Danes boycotting Coca-Cola, says Carlsberg

Next Article

SPOR and XEVMPD status update webinar, Broadcast, from 9 April 2025, 10:00 (CEST...

Related Posts

As pharma industry's reputation slips again, ViiV retains top spot among patient groups: survey

As pharma industry's reputation slips again, ViiV retai...

Apr 29, 2025  0

Regulatory tracker: Pfizer's hemophilia drug Hympavzi scores nod in UK

Regulatory tracker: Pfizer's hemophilia drug Hympavzi s...

Apr 22, 2025  0

Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B

Pfizer, in sweeping cost cutting push, lifts overall sa...

Apr 29, 2025  0